AT1

0.00%

2.8¢ atomo diagnostics limited

Imo you did not understand what AT1 is actually developing. As...

First 893 Last

Share
Profile

Follow
zoltar

444 Posts.

48

17/06/20

07:19

Post #: 45264432
Share

Originally posted by bulktrading: ↑

Some thoughts/questions about AT1:
Can anyone clarify why AT1 developed a new pregnancy test? Current pee-based tests are >99% accurate, cheap (couple of dollars) and readily accessible. To me, it sort of seems they tried to reinvent the wheel. Surely the market for a new pregnancy test is limited as is the need for higher accuracy. Their time/money could have been better spent developing tests for conditions that have no testing, inaccurate testing, expensive testing, etc. Are they struggling to identify new applications for their self-testing IP?
Also, whilst the Covid19 test currently has a high demand, if/when a vaccine is developed (maybe later this year), the demand for these tests will plummet and so will their revenue.
As for their HIV test, I get that it has a place and will benefit a lot of people. But the Mylan badged test sells for as little as 5USD in various places around the world. Assuming AT1 gets $1 of that as a royalty, it needs to sell tens of millions to justify their current market cap of $160m. In the last 5yrs they have sold ~1m HIV tests and their cumulative lifetime revenue is barely in the millions - this indicates they generate minimal revenue from each test. Additionally, in western countries, people already get HIV tested as a part of STI checks - why pay more for an on-the-spot test when you still have to wait for the results for everything else? Where is the high-margin market coming from?
In my mind, for AT1 to be a winner, it needs to develop a number of new tests for various conditions - the covid boom is short lived, the pregnancy test has a small market and I'm not convinced about the upside from the HIV test.
Keen to hear your thoughts. Just offering a different point of view.

Expand

Imo you did not understand what AT1 is actually developing. As mentioned so many times they simply develop the hardware that can accommodate any number of blood testing (for people and veterinary usage) ... Their revenue will grow with scalability and they are in the first phase of the process this year. What they did with NG Bio can be done with many other companies that will develop test strips.

AT1 Price at posting: 29.0¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

ASX hits all time high out the gate on Friday trades following bullish US inflation data

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Bitcoin investors need to know the risks

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

There are more pages in this discussion • 496 more messages in this thread...

First 893 Last

Add AT1 (ASX) to my watchlist

(20min delay)
Last 2.8¢		Change 0.000(0.00%)		Mkt cap ! $17.89M

Open	High	Low	Value	Volume
2.7¢	2.8¢	2.5¢	$3.866K	140.1K

Buyers (Bids)

No.	Vol.	Price($)
4	472951	2.5¢

Sellers (Offers)

Price($)	Vol.	No.
2.8¢	143054	2

View Market Depth

No.	Vol.	Price($)
4	472951	0.025
2	617050	0.024
3	893000	0.023
7	604373	0.022
4	432292	0.021

Price($)	Vol.	No.
0.028	143054	2
0.029	452248	7
0.030	430739	8
0.031	196496	4
0.033	367586	3

Last trade - 16.10pm 12/07/2024 (20 minute delay)

AT1 (ASX) Chart

Imo you did not understand what AT1 is actually developing. As...

Immutep reports strong response rate from immunotherapies treating carcinomas

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

ASX hits all time high out the gate on Friday trades following bullish US inflation data

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Bitcoin investors need to know the risks

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nimy to raise $1.21M to explore 'newsy' WA targets

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Imo you did not understand what AT1 is actually developing. As...

Top Stories

Immutep reports strong response rate from immunotherapies treating carcinomas

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

ASX hits all time high out the gate on Friday trades following bullish US inflation data

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Bitcoin investors need to know the risks

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nimy to raise $1.21M to explore 'newsy' WA targets

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News